Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Weighted Average and Diluted) (2022 - 2026)

Insight Molecular Diagnostics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.74 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 67.83% to -$0.74 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.64, a 65.62% increase, with the full-year FY2025 number at -$1.65, up 64.59% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.74 in Q4 2025 for Insight Molecular Diagnostics, down from -$0.34 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for IMDX hit a ceiling of $0.4 in Q1 2023 and a floor of -$8.16 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.31 across 4 years, with a median of -$0.9 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 1100.0% in 2023 and later crashed 382.5% in 2024.
  • Tracing IMDX's EPS (Weighted Average and Diluted) over 4 years: stood at -$8.16 in 2022, then surged by 78.75% to -$1.73 in 2023, then tumbled by 32.62% to -$2.3 in 2024, then soared by 67.83% to -$0.74 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for IMDX at -$0.74 in Q4 2025, -$0.34 in Q3 2025, and -$0.3 in Q2 2025.